Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Phase II Study of New Direct-Acting Antiviral Agent, HARVONI® (Ledipasvir/Sofosbuvir), for the Treatment of Genotype 1 or 2 HCV-Associated Indolent B-Cell Non- Hodgkin's Lymphoma

NCT03261349 is registered in ClinicalTrials.gov with National Taiwan University Hospital as lead sponsor.

NCT NCT03261349
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03261349 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Phase II Study of New Direct-Acting Antiviral Agent, HARVONI® (Ledipasvir/Sofosbuvir), for the Treatment of Genotype 1 or 2 HCV-Associated Indolent B-Cell Non- Hodgkin's Lymphoma
Lead sponsor
National Taiwan University Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
September 1, 2017
Completion date
August 15, 2021
Enrollment
21 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

indolent lymphoma